Skip to content


Sensipar, Mimpara (cinacalcet) is a small molecule pharmaceutical. Cinacalcet was first approved as Sensipar on 2004-03-08. It is used to treat parathyroid neoplasms, primary hyperparathyroidism, and secondary hyperparathyroidism in the USA. It has been approved in Europe to treat hypercalcemia, hyperparathyroidism, parathyroid neoplasms, and secondary hyperparathyroidism. The pharmaceutical is active against extracellular calcium-sensing receptor. In addition, it is known to target metabotropic glutamate receptor 5. Sensipar's patent is valid until 2026-09-22 (FDA).
Trade Name Mimpara
Common Name Cinacalcet
Indication hypercalcemia, hyperparathyroidism, parathyroid neoplasms, primary hyperparathyroidism, secondary hyperparathyroidism
Drug Class Calcium receptor agonists
Get full access now